medigraphic.com
Boletín Médico del Hospital Infantil de México

2006, Número 4

<< Anterior

Bol Med Hosp Infant Mex 2006; 63 (4)


Uso de tacrolimus en pediatría

Reyes-Pérez H, Medeiros-Domingo M

Idioma: Español
Referencias bibliográficas: 76
Paginas: 276-285
Archivo PDF: 161.55 Kb.


RESUMEN

El tacrolimus es un fármaco inmunosupresor inhibidor de calcineurina utilizado principalmente para prevenir el rechazo de órganos sólidos. También se emplea como inmunosupresor de segunda línea en otras enfermedades de origen inmunológico entre las que destacan: síndrome nefrótico, lupus eritematoso sistémico, dermatitis atópica, vitíligo y psoriasis entre otras.
En este artículo se revisa la farmacocinética, monitoreo terapéutico, efectos adversos y toxicidad del tacrolimus en pacientes pediátricos, haciendo énfasis en los padecimientos en los que ha demostrado utilidad.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Pollock-Barziv SM, Dipchand AI, McCrindle BW, Nalli N, West LJ. Randomized clinical trial of tacrolimus vs cyclosporine-based immunosuppression in pediatric heart transplantation: preliminary results at 15-month follow-up. J Heart Lung Transplant. 2005; 24: 190-4.

  2. Peura JL, Zile MR, Feldman DS, VanBakel AB, McClure C, Uber W, et al. Effects of conversion from cyclosporine to tacrolimus on left ventricular structure in cardiac allograft recipients. J Heart Lung Transplant. 2005; 24: 1969-72.

  3. Fung JJ. Tacrolimus and transplantation: a decade in review. Transplantation. 2004; 77: S41-3.

  4. Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet. 1995; 29: 404-30.

  5. Ingels SC, Koenig J, Scott MG. Stability of FK506 (tacrolimus) in whole-blood specimens. Clin Chem. 1995; 41: 1320-1.

  6. Bartlomiejczyk I, Zochowska D, Sanko-Resmer J, Matuszewicz D, Paczek L. Therapeutic monitoring of tacrolimus concentrations in blood of renal and liver trans plant recipients: comparison of microparticle enzyme immunoassay and enzyme multiplied immunoassay methods. Transplant Proc. 2006; 38: 94-6.

  7. Webb NJ, Roberts D, Preziosi R, Keevil BG. Fingerprick blood samples can be used to accurately measure tacrolimus levels by tandem mass spectrometry. Pediatr Transplant. 2005; 9: 729-33.

  8. Jusko WJ, Piekoszewski W, Klintmalm GB, Shaefer MS, Hebert MF, Piergies AA, et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther. 1995; 57: 281-90.

  9. French AE, Soldin SJ, Soldin OP, Koren G. Milk transfer and neonatal safety of tacrolimus. Ann Pharmacother. 2003; 37: 815-8.

  10. Kaplan B, Lown K, Craig R, Abecassis M, Kaufman D, Leventhal J, et al. Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient: possible relationship to intestinal P-glycoprotein activity. Transplantation. 1999; 67: 333-5.

  11. Masuda S, Uemoto S, Goto M, Fujimoto Y, Tanaka K, Inui K. Tacrolimus therapy according to mucosal MDR1 levels in small-bowel transplant recipients. Clin Pharmacol Ther. 2004; 75: 352-61.

  12. Hashida T, Masuda S, Uemoto S, Saito H, Tanaka K, Inui K. Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation. Clin Pharmacol Ther. 2001; 69: 308-16.

  13. Maezono S, Sugimoto K, Sakamoto K, Ohmori M, Hishikawa S, Mizuta K, et al. Elevated blood concentrations of calcineurin inhibitors during diarrheal episode in pediatric liver transplant recipients: involvement of the suppression of intestinal cytochrome P450 3A and P-glycoprotein. Pediatr Transplant. 2005; 9: 315-23.

  14. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004; 43: 623-53.

  15. Mancinelli LM, Frassetto L, Floren LC, Dressler D, Carrier S, Bekersky I, et al. The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther. 2001; 69: 24-31.

  16. Plosker GL, Foster RH. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs. 2000; 59: 323-89.

  17. Wallemacq PE, Verbeeck RK. Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. Clin Pharmacokinet. 2001; 40: 283-95.

  18. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology—drug disposition, action, and therapy in infants and children. N Engl J Med. 2003; 349: 1157-67.

  19. McDiarmid SV, Colonna JO 2nd, Shaked A, Vargas J, Ament ME, Busuttil RW. Differences in oral FK506 dose requirements between adult and pediatric liver transplant patients. Transplantation. 1993; 55: 1328-32.

  20. Filler G, Grygas R, Mai I, Stolpe HJ, Greiner C, Bauer S, et al. Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with renal transplants. Nephrol Dial Transplant. 1997; 12: 1668-71.

  21. Khalaf H, Al-Asseri A, Bhuiyan J, Nafea O, Al-Sebayel M. Tacrolimus (FK 506) given three times daily after liver transplantation for minimizing nephrotoxicity and neurotoxicity. Transplant Proc. 2003; 35: 2787-8.

  22. Mollison KW, Fey TA, Krause RA, Andrews JM, Bretheim PT, Cusick PK, et al. Nephrotoxicity studies of the immunosuppressant tacrolimus (FK506) and ascomycin in rat models. Toxicology. 1998; 125: 169-81.

  23. Ogita K. Renal tubular acidosis secondary to FK506 in living donor liver transplantation: A case report. Asian J Surg. 2003; 26: 218-20.

  24. Quiros-Tejeira RE, Chang IF, Bristow LJ, Karpen SJ, Goss JA. Treatment of acute tacrolimus whole-blood elevation with phenobarbital in the pediatric liver transplant recipient. Pediatr Transplant. 2005; 9: 792-6.

  25. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000; 38: 41-57.

  26. Banerjee R, Leaver N, Lyster H, Banner NR. Coadministration of itraconazole and tacrolimus after thoracic organ transplantation. Transplant Proc. 2001; 33: 1600-2.

  27. Christians U, Jacobsen W, Benet LZ, Lampen A. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet. 2002; 41: 813-51.

  28. Tada H, Yanagiwara S, Ito K, Suzuki T. Role of diltiazem on tacrolimus pharmacokinetics in tacrolimus-induced nephrotoxic rats. Pharmacol Toxicol. 1999; 84: 241-6.

  29. Toda F, Tanabe K, Ito S, Shinmura H, Tokumoto T, Ishida H, et al. Tacrolimus trough level adjustment after administration of fluconazole to kidney recipients. Transplant Proc. 2002; 34: 1733-5.

  30. van Gelder T. Drug interactions with tacrolimus. Drug Saf. 2002; 25: 707-12.

  31. Buck ML. Pharmacokinetic changes during extracorporeal membrane oxygenation: implications for drug therapy of neonates. Clin Pharmacokinet. 2003; 42: 403-17.

  32. Page RL 2nd, Klem PM, Rogers C. Potential elevation of tacrolimus trough concentrations with concomitant metronidazole therapy. Ann Pharmacother. 2005; 39: 1109-13.

  33. Shitrit D, Ollech JE, Ollech A, Bakal I, Saute M, Sahar G, et al. Itraconazole prophylaxis in lung transplant recipients receiving tacrolimus (FK 506): efficacy and drug interaction. J Heart Lung Transplant. 2005; 24: 2148-52.

  34. Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW, et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther. 1997; 62: 41-9.

  35. Hebert MF, Fisher RM, Marsh CL, Dressler D, Bekersky I. Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol. 1999; 39: 91-6.

  36. Hebert MF, Park JM, Chen YL, Akhtar S, Larson AM. Effects of St. John’s wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol. 2004; 44: 89-94.

  37. Jones TE, Morris RG. Pharmacokinetic interaction between tacrolimus and diltiazem: dose-response relationship in kidney and liver transplant recipients. Clin Pharmacokinet. 2002; 41: 381-8.

  38. Ocran KW, Plauth M, Mai I, Lochs H. Tacrolimus toxicity due to drug interaction with mibefradil in a patient after liver transplantation. Z Gastroenterol. 1999; 37: 1025-8.

  39. Moreau C, Taburet AM, Furlan V, Debray D, Loriot MA. Interaction between tacrolimus and omeprazole in a pediatric liver transplant recipient. Transplantation. 2006; 81: 487-8.

  40. Hu RH, Lee PH, Tsai MK. Clinical influencing factors for daily dose, trough level, and relative clearance of tacrolimus in renal transplant recipients. Transplant Proc. 2000; 32: 1689-92.

  41. Undre NA, Schafer A. Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation. European Tacrolimus Multicentre Renal Study Group. Transplant Proc. 1998; 30: 1261-3.

  42. Christiaans M, van Duijnhoven E, Beysens T, Undre N, Schafer A, van Hooff J. Effect of breakfast on the oral bioavailability of tacrolimus and changes in pharmacokinetics at different times posttransplant in renal transplant recipients. Transplant Proc. 1998; 30: 1271-3.

  43. Braun F, Schutz E, Peters B, Talaulicar R, Grupp C, Undre N, et al. Pharmacokinetics of tacrolimus primary immunosuppression in kidney transplant recipients. Transplant Proc. 2001; 33: 2127-8.

  44. Cantarovich M, Fridell J, Barkun J, Metrakos P, Besner JG, Deschenes M, et al. Optimal time points for the prediction of the area-under-the-curve in liver transplant patients receiving tacrolimus. Transplant Proc. 1998; 30: 1460-1.

  45. Jorgensen KA, Povlsen JV, Madsen S, Madsen M, Hansen HE, Pedersen AR, et al. Two-hour blood tacrolimus levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal transplant patients. Transplant Proc. 2002; 34: 1721-2.

  46. Jorgensen K, Povlsen J, Madsen S, Madsen M, Hansen H, Pedersen A, et al. C2 (2-h) levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal-transplant patients. Nephrol Dial Transplant. 2002; 17: 1487-90.

  47. Pisitkun T, Eiam-Ong S, Chusil S, Praditpornsilpa K, Pansin P, Tungsanga K. The roles of C4 and AUC0-4 in monitoring of tacrolimus in stable kidney transplant patients. Transplant Proc. 2002; 34: 3173-5.

  48. Ragette R, Kamler M, Weinreich G, Teschler H, Jakob H. Tacrolimus pharmacokinetics in lung transplantation: new strategies for monitoring. J Heart Lung Transplant. 2005; 24: 1315-9.

  49. Di Filippo S, Zeevi A, Mc Dade K, Bastien O, Webber S. Impact of TGFb1 gene polymorphisms on acute and chronic rejection in pediatric heart transplant allografts. Transplantation. 2006; 81: 934-9.

  50. Albornoz-Lopez R, Aumente-Rubio MD, Arizon-del Prado JM, Cardenas- Aranzana M, Lopez-Malo de Molina MD, Gago-Sanchez AI. [Tacrolimus blood levels and incidence of graft rejection in heart transplantation]. Farm Hosp. 2005; 29: 158-63.

  51. Medeiros M, Pérez-Urizar J, Muñoz R, Castañeda-Hernández G. Limited sampling model for area-under-the-curve monitoring in pediatric patients receiving either Sandimmune or Neoral cyclosporin A oral formulations. Pediatr Transplant. 1999; 3: 225-30.

  52. Ku YM, Min DI. An abbreviated area-under-the-curve monitoring for tacrolimus in patients with liver transplants. Ther Drug Monit. 1998; 20: 219-23.

  53. Stolk LM, van Duijnhoven EM, Christiaans MH, van Hooff JP. Trough levels of tacrolimus. Ther Drug Monit. 2002; 24: 573; author reply 573-4.

  54. Uchida K, Tominaga Y, Haba T, Katayama T, Matsuoka S, Sato T, et al. Usefulness of monitoring of AUC(0-4h) during the induction period of immunosuppressive therapy with tacrolimus after renal transplantation. Transplant Proc. 2002; 34: 1736-7.

  55. Filler G, Feber J, Lepage N, Weiler G, Mai I. Universal approach to pharmacokinetic monitoring of immunosuppressive agents in children. Pediatr Transplant. 2002; 6: 411-8.

  56. Yocum DE, Furst DE, Bensen WG, Burch FX, Borton MA, Mengle-Gaw LJ, et al. Safety of tacrolimus in patients with rheumatoid arthritis: long-term experience. Rheumatology (Oxford). 2004; 43: 992-9.

  57. Loeffler K, Gowrishankar M, Yiu V. Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome. Pediatr Nephrol. 2004; 19: 281-7.

  58. Meyrier A. Treatment of focal segmental glomerulosclerosis. Expert Opin Pharmacother. 2005; 6: 1539-49.

  59. Tang S, Tang AW, Tam MK, Ho YW. Use of tacrolimus in steroid- and cyclophosphamide-resistant minimal change nephrotic syndrome. Am J Kidney Dis. 2003; 42: E13-5.

  60. Duncan N, Dhaygude A, Owen J, Cairns TD, Griffith M, McLean AG, et al. Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy. Nephrol Dial Transplant. 2004; 19: 3062-7.

  61. Mok CC, Tong KH, To CH, Siu YP, Au TC. Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. Kidney Int. 2005; 68: 813-7.

  62. Politt D, Heintz B, Floege J, Mertens PR. Tacrolimus- (FK 506) based immunosuppression in severe systemic lupus erythematosus. Clin Nephrol. 2004; 62: 49-53.

  63. Simpson D, Noble S. Tacrolimus ointment: a review of its use in atopic dermatitis and its clinical potential in other inflammatory skin conditions. Drugs. 2005; 65: 827-58.

  64. Woo DK, James WD. Topical tacrolimus: a review of its uses in dermatology. Dermatitis. 2005; 16: 6-21.

  65. Koo JY, Fleischer AB Jr., Abramovits W, Pariser DM, McCall CO, Horn TD, et al. Tacrolimus ointment is safe and effective in the treatment of atopic dermatitis: results in 8 000 patients. J Am Acad Dermatol. 2005; 53: S195-205.

  66. Frohna JG. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. J Pediatr. 2005; 147: 126.

  67. Kanwar AJ, Dogra S, Parsad D. Topical tacrolimus for treatment of childhood vitiligo in Asians. Clin Exp Dermatol. 2004; 29: 589-92.

  68. Silverberg NB, Lin P, Travis L, Farley-Li J, Mancini AJ, Wagner AM, et al. Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases. J Am Acad Dermatol. 2004; 51: 760-6.

  69. Carroll CL, Clarke J, Camacho F, Balkrishnan R, Feldman SR. Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment. Arch Dermatol. 2005; 141: 43-6.

  70. Steele JA, Choi C, Kwong PC. Topical tacrolimus in the treatment of inverse psoriasis in children. J Am Acad Dermatol. 2005; 53: 713-6.

  71. Saripalli YV, Gadzia JE, Belsito DV. Tacrolimus ointment 0.1% in the treatment of nickel-induced allergic contact dermatitis. J Am Acad Dermatol. 2003; 49: 477-82.

  72. Goldman D. Tacrolimus ointment for the treatment of steroid-induced rosacea: a preliminary report. J Am Acad Dermatol. 2001; 44: 995-8.

  73. Bamford JT, Elliott BA, Haller IV. Tacrolimus effect on rosacea. J Am Acad Dermatol. 2004; 50: 107-8.

  74. Braza TJ, DiCarlo JB, Soon SL, McCall CO. Tacrolimus 0.1% ointment for seborrhoeic dermatitis: an open-label pilot study. Br J Dermatol. 2003; 148: 1242-4.

  75. Meshkinpour A, Sun J, Weinstein G. An open pilot study using tacrolimus ointment in the treatment of seborrheic dermatitis. J Am Acad Dermatol. 2003; 49: 145-7.

  76. Eisman S, Orteu CH. Recalcitrant erosive flexural lichen planus: successful treatment with a combination of thalidomide and 0.1% tacrolimus ointment. Clin Exp Dermatol. 2004; 29: 268-70.




2020     |     www.medigraphic.com